Fabtech Cleanrooms Reports 74.88% Revenue Growth in H1 FY27; Order Book Reaches Rs 470 Crore
Fabtech Cleanrooms Limited reported consolidated revenue from operations of Rs.133.23 crore in H1 FY27, compared with Rs.76.19 crore in H1 FY26, registering year-on-year growth of 74.88%. Total income increased to Rs.134.00 crore from Rs.77.20 crore in the corresponding period.
EBITDA increased by 75.13% to Rs.10.28 crore from Rs.5.87 crore in H1 FY26. EBITDA margin stood at 7.67%, compared with 7.60% in the corresponding period.
Profit Before Tax (PBT) increased to Rs.8.17 crore from Rs.5.33 crore. Consolidated Profit After Tax (PAT) rose by 54.65% to Rs.5.15 crore from Rs.3.33 crore in H1 FY26. However, PAT margin declined to 3.86% from 4.37%.
Fabtech Cleanrooms Order Book and Business Pipeline
Fabtech Cleanrooms reported its highest-ever order book of approximately Rs.470 crore as of October 2026, more than doubling the Rs.199 crore order book reported on March 31, 2026.
The company has an active pipeline of approximately Rs.600 crore out of a total offered pipeline of Rs.1,250 crore, reflecting business opportunities across its key operating sectors.
Order ticket sizes are increasing, particularly in the microelectronics and life sciences segments. The company has also secured a marquee single-ticket order of approximately Rs.90 crore in the life sciences segment, strengthening its presence in larger project execution.
Management expects higher project volumes in Q3 and Q4 FY27, with improved execution and operating leverage supporting margin recovery.
Fabtech Cleanrooms Operational and Business Updates
Fabtech Cleanrooms recorded broad-based growth during H1 FY27, supported by higher execution across pharmaceutical, data centre and solar projects.
The company's subsidiary, Kelvin Air Conditioning & Ventilation Systems, in which Fabtech holds a 62.20% stake, continues to expand its HVAC business, with a particular focus on data centre orders and turnkey cleanroom HVAC requirements.
The company is strengthening its manufacturing capabilities through a new facility in Hyderabad to support its growing order book.
Additionally, Fabtech is expanding its presence in automotive, medical devices, electrical and electronic components, complementing its established pharmaceutical, biotechnology and healthcare businesses.
The company's associate, AAR-T, is strengthening its presence in the semiconductor industry through import-substituting T-grid technology, supported by specialised design and engineering capabilities.
Fabtech Cleanrooms Margin and Working Capital Updates
During H1 FY27, EBITDA margin stood at 7.67%, compared with 7.60% in H1 FY26, while PAT margin declined to 3.86% from 4.37%.
The company highlighted aluminium and key raw material price volatility, geopolitical uncertainty and competitive pricing in newer sectors as factors affecting profitability.
Fabtech Cleanrooms reported trade receivables of Rs.129.10 crore as of September 30, 2026, reflecting higher execution and milestone-linked payments on strategic reference-building projects.
As these projects approach completion, the company expects improved working capital efficiency through greater order selectivity, stronger pricing power and better commercial terms. Management expects the working capital cycle to improve by March-April 2027.
The company has also secured enhanced banking facilities to support the execution of its larger order book and fund working capital requirements as execution scales up in H2 FY27.
Fabtech Cleanrooms Management Commentary
Mr. Anup Manohar Munshi, Chief Executive Officer of Fabtech Cleanrooms Limited, highlighted the company's revenue growth and expanding order book.
He stated that H1 FY27 revenue from operations grew by nearly 75%, while the company entered the second half of FY27 with an order book of approximately Rs.470 crore.
He also highlighted increasing order ticket sizes, repeat orders and an active business pipeline of approximately Rs.600 crore.
Management expects higher project volumes in Q3 and Q4 FY27 to support margin recovery, aided by expanded execution, operating leverage and enhanced banking facilities.
The company also expects its growing presence in data centres, automotive, medical devices and electronics to create additional business opportunities.
Fabtech Cleanrooms Financial and Operational Highlights
| Particulars | H1 FY27 Details |
| Revenue from Operations | Rs.133.23 crore, up 74.88% YoY |
| Total Income | Rs.134.00 crore |
| EBITDA | Rs.10.28 crore, up 75.13% YoY |
| EBITDA Margin | 7.67%, compared with 7.60% in H1 FY26 |
| Profit Before Tax | Rs.8.17 crore |
| Consolidated Profit After Tax | Rs.5.15 crore, up 54.65% YoY |
| PAT Margin | 3.86%, compared with 4.37% in H1 FY26 |
| Order Book | Approximately Rs.470 crore |
| Active Order Pipeline | Rs.600 crore |
| Total Offered Pipeline | Rs.1,250 crore |
| Marquee Order | Approximately Rs.90 crore in the life sciences segment |
| Trade Receivables | Rs.129.10 crore as of September 30, 2026 |
| Key Growth Segments | Pharmaceuticals, data centres, solar, microelectronics and life sciences |
| Subsidiary | Kelvin Air Conditioning & Ventilation Systems (62.20%) |
| Capacity Expansion | New manufacturing facility in Hyderabad |
| Management | Anup Manohar Munshi, Chief Executive Officer |
What to Watch Next
- Investors may track the execution of Fabtech Cleanrooms' order book and the conversion of its Rs.600 crore active pipeline into confirmed orders.
- The company's ability to execute its expanded order book, particularly during Q3 and Q4 FY27, will be important for revenue growth and operating margin improvement.
- Investors can also monitor the expansion of the Hyderabad manufacturing facility, the growth of the subsidiary's data centre HVAC business and the company's expansion into microelectronics, automotive and medical devices.
- Further attention may be given to working capital management, particularly the reduction in trade receivables, raw material cost fluctuations and the company's ability to improve PAT margins while executing larger projects.
Disclaimer
Investments in the securities market are subject to market risks. Read all related documents carefully before investing. Registration granted by SEBI, and certification from NISM in no way guarantee the performance of the intermediary or provide any assurance of returns to investors. Choice Equity Broking Private Limited: SEBI Reg No. Broking - INZ000160131 ( BSE - 3299 ) | ( NSE - 13773 ) | ( MSEI - 73200 ) | ( MCX - 40585 ) | ( NCDEX - 01006 ). Depository Participant SEBI Reg. No. - IN - DP - 84 - 2015, DP ID CDSL - 12066900, NSDL ID - IN301895. Research Analyst - INH000000222 (CIN. NO.: U65999MH2010PTC198714)
Other News
Natco Pharma Promoters and Promoter Group Acquire 22.11 Lakh Shares Through Rights Issue
Natco Pharma Limited’s promoters and promoter group entities have acquired 22,11,776 equity shares through the company’s Rights Issue. The shares were allotted on October 26, 2026, at Rs 750 per share, taking the total value of acquisition to about Rs. 165.88 crore. The company’s paid up equity share capital increased to 19,61,67,952 equity shares following the Rights Issue.
Jio Financial Services Allots 25 Crore Shares to Promoter Group Entities
Jio Financial Services Limited has allotted 25 crore equity shares to two promoter group entities following the conversion of preferential warrants. The allotment was made at Rs.316.50 per share, including a face value of Rs.10 and a premium of Rs.306.50 per share.
Ginni Filaments: SBICAP Trustee Releases Encumbrance on 26.48 Lakh Shares
SBICAP Trustee Company Limited has disclosed the release of encumbrance on 26,48,300 equity shares of Ginni Filaments Limited under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The released shares represent 3.09% of the total voting share capital of Ginni Filaments. Following the transaction dated October 29, 2026, SBICAP Trustee's encumbered shareholding declined from 1,04,08,300 equity shares (12.15%) to 77,60,000 equity shares (9.06%). The transaction was executed by SBICAP Trustee Company Limited in its capacity as a Security Trustee. The entity does not belong to the promoter or promoter group of Ginni Filaments.